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By 
Victoria J. Smith 
 
ABSTRACT 
The medical device industry is a prominent and lucrative industry in the USA that benefits the country by 
both improving health and improving the economy.  As this industry is heavily regulated, marketers in the 
medical device industry are faced with unique challenges.  Unfortunately, due to the nature of this industry, 
marketing strategies pertaining to medical devices are often over-looked by researchers and scholars. The 
purpose of this research is to gain insight and better understand the importance of two key clinical 
marketing strategies employed by medical device companies: key opinion leader (KOL) strategies and 
evidence-based medicine (EBM) strategies. Nine medical device companies that market medical device 
innovations were interviewed regarding these two strategies and how/if they have contributed to the 
company’s success.  The results were analyzed so patterns and similarities linking these strategies to 
measures of success could be examined.  The results suggested that a KOL strategy is highly important and 
always used and that companies that pay their KOLs are more likely to have sales.  In order to attract and 
recruit KOLs, the most used strategies included networking and requesting references.  The interviews also 
revealed that KOLs are likely to pay for products, unless they are researchers in an academic setting.  With 
regards to EBM strategies, the interviews indicated that an EBM strategy is not always necessary to achieve 
sales.  Further, the interviews indicated that employing a KOL and EBM strategy may leverage other 
strategies.  When measuring success, the interviews indicated that sales were a key indicator of success.  
Lastly, early stage companies are less likely to have sales than mid-late stage companies and companies 
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The healthcare system in the United States continues to face increasing costs despite 
government interventions and policies.  Now, more than ever, it is important to nurture 
the development of medical device innovations, which will ultimately provide faster, 
cheaper, safer and more efficient patient care.   
 
The mix of modern technology and medicine has led to substantial advances in the health 
outcomes of people around the world.1  Notable advances include pacemakers, dental 
lasers, automatic defibrillators (AEDs), cochlear implants, robotics in surgery, prosthetic 
hearts and cardiac stents. These medical device innovations present a profoundly new 
opportunity for both physicians and patients.2
,3 Given the tremendous historic, and 
potential future, impact of medical device innovation on healthcare in the United States, it 
is critically important to better understand the characteristics of these innovations, 
particularly marketing strategies, that will undoubtedly ensure their success in the 
marketplace. 
 
The purpose of this research is to gain insight and better understand the importance of 
two key clinical marketing strategies employed by medical device companies: key 
opinion leaders (KOL) and evidence-based medicine (EBM).  By better understanding the 
impact of these strategies, medical device marketers can construct effective marketing 
strategies that will be guided by tested and proven methods.  The results of this study will 
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inform strategic decisions and therefore will be important to companies that are 
developing marketing strategies for medical device innovations. 
Literature Review 
Medical Devices 
Medical technology products are ‘medical devices’ which cover “any instrument, 
apparatus, appliance, materials or other article, whether used alone or in combination, 
including the software necessary for its proper application intended by the manufacturer 
to be used for human beings for the purpose of diagnosis, prevention, monitoring, 
treatment or alleviation of disease or an injury or a physiological process”.4  Medical 
devices are extremely important, as healthcare delivery and advancement 
would not be possible without them.  In 2006, the global medical market reached $209 
billion5, however the United States (USA) is the largest medical device market in the 
world with a market size of around $110 billion, and it is expected to reach $133 billion 
by 2016.6  To put this number in perspective, the USA is home to more than 6,500 
medical device companies, mainly small and medium-sized enterprises (SMEs), making it 
one of the country's largest industries and exports.  According to the Food and Drug 
Administration (FDA), 4,262 medical devices were released into the US market in 2002.7  
In addition to the clear economic importance of medical devices, these products are 
essential in reducing healthcare costs and increasing patient welfare.  
 
Medical devices are heavily regulated in the USA and most other parts of the developed 
world.  In the USA, the FDA is the governing body that regulates, among other things, 
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medical devices. The FDA has established classifications for approximately 1,700 
different types of devices and grouped them into 16 medical specialties.  These 16 
medical specialties are as follows: Anesthesiology; Cardiovascular; Chemistry; Dental; 
Ear, Nose, and Throat; Gastroenterology and Urology; General and Plastic Surgery; 
General Hospital; Hematology; Immunology; Microbiology; Neurology; Obstetrical and 
Gynecological; Ophthalmic; Orthopedic; Pathology; Physical Medicine; Radiology; 
Toxicology.  Each of these types of devices can then be classified to one of three 
regulatory classes based on the level of control necessary to ensure the safety and 
effectiveness of the device. The three classes and the requirements are as follows: 
 Class I (General Controls) 
o With Exemptions 
o Without Exemptions 
 Class II (General Controls and Special Controls) 
o With Exemptions 
o Without Exemptions 
 Class III (General Controls and Premarket Approval) 
 
While “medical device” is a rather broad term, it can be further segmented into “medical 
device innovations”.  The main difference being that medical device innovations are 
produced by knowledge gained from scientific research or by overcoming an engineering 
problem (i.e., applying existing knowledge to new problems). Typically, patents are used 
to measure medical device innovation.  A medical device innovation is differentiated 
from a general medical device based on the following parameters: 
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 It is not medical supplies or disposables 
 The product is new and innovative (i.e., serves a new use) 
 An innovation is defined as any product, idea or practice that is viewed as new by 
an individual or the adopting unit 8 
 Interacts with a person’s physiology 
 Science-based 
 Class II or Class III  
 
Additionally, the following can identify medical device innovation9:  
 Based on engineering problem solving by individuals or small enterprises 
 Incremental rather than radical 
 Rarely depends on results of long-term scientific research  
 Does not reflect the recent graduation of fundamental knowledge 
 
In order for medical innovations to be successful, they must solve an unmet medical need 
or reduce healthcare costs. Otherwise, adoption will not occur. It is important for the user 
and/or the buyer to understand how a medical device innovation will either reduce costs 
or increase care – preferably both.  In order for this message to be adequately delivered, 
companies rely on effective marketing strategies. 
Marketing Strategies 
Marketing strategies are critical to the success of any company.  As defined by David 
Aaker: “a process that can allow an organization to concentrate its resources on the 
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optimal opportunities with the goals of increasing sales and achieving a sustainable 
competitive advantage.”10 Marketers in all industries are faced with various hurdles; 
however, marketers in the medical device industry face novel and unique challenges.11  
This could be because the medical device industry is heavily regulated, the purchasing 
decision is based on multiple factors (i.e., safety, efficacy, efficiency, politics) and 
marketing requires a combination of medical, scientific and business knowledge.
12,13
  
Innovative medical devices require specific and focused marketing strategies that are 
unlike most other newly released products.  Therefore, it is important for medical device 
companies to embrace tested and successful medical device marketing strategies in order 
for their innovations to be adopted by the medical community.   
 
There are numerous factors that have been shown to increase customer acceptance/buy-in 
of medical innovations including (but not limited to): evidence for clinical benefits, 
economic benefits and increased patient welfare; product safety; transfer of evidence into 
clinical practice (e.g. clinical guideline development); and expanding product use to new 
indications. Medical device companies heavily rely on marketing strategies to increase 
adoption; however, due to regulations and the very nature of the medical devices, 
marketing strategies in this industry are very different from standard industries, say, 
consumer products.  Much like the entertainment industry14 and the high-tech industry,15 
marketing in the medical device industry requires specific knowledge and strategies. 







 exposure through trade shows and exhibits,
19
 
direct marketing via a savvy sales team, key opinion leader (KOL) programs
20
 and 






In the literature, two clinical marketing strategies were notably more prominent.  These 
two strategies were a Key Opinion Leader (KOL) strategy and Evidenced-Based 
Medicine (EBM) strategy.
22,23
  Key opinion leaders are a source of information, influence 
and an important determinant of adopting or avoiding new treatments. It is widely 
believed in the industry that physician-led peer review of new medical technology is the 
top best practice when making purchasing decisions.24
,25 Evidenced-based medicine 
emphasizes the use of evidence from well-designed and conducted research in healthcare 
decision-making.  This strategic marketing tactic has been known to increase customer 
adoption and market penetration.26   
Key Opinion Leader (KOL) Strategy 
The term “key opinion leader” was coined in 1955 by Katz and Larzarsfeld when they 
described an individual’s decision-making process.27  Since then, the term was been 
widely accepted as a marketing principle. The profound influence of a person’s peers on 
behavior and decision-making has been well documented throughout social psychology 
literature.  For many years, marketers in many industries have taken advantage of this 
psychological principle in order to boost sales.  It is no surprise that this phenomenon 
transcends to the medical device industry.  A key opinion leader (KOL) (also known as an 
opinion leader, thought leader or product champion) has been identified anecdotally and 
in the literature as a critical factor related to adoption of medical device innovations.  
Studies related to innovation diffusion in medicine dating back to 1966 identified the 
physicians association with opinion leaders as a source of information, influence and an 
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important determinant of the adoption or avoidance of new treatments.28  More recently, a 
2013 Deloitte annual survey
29
 of U.S. physicians revealed that 70 percent of U.S. 
physicians believe that physician-led peer review of new medical technology is the top 
best practice when making purchasing decisions.  In fact, studies have found that every 
local medical community has a small group of easily identifiable physicians who are 
influential in facilitating new learning and adoption of new medical products; these 
opinion leaders are looked up to by their colleagues for advice and unbiased 
information.30 
 
When attempting to understand medical KOLs, they can be sub-divided into “market 
leaders” and “clinical leaders”.  Market leaders are tightly connected to the local patient 
and physician communities. They are typically general practitioners with large practices 
who gain recognition through the satisfaction and loyalty of their patients.  According to 
“Best Practices”, a leading benchmarking, consulting and advisory services firm serving 
biopharmaceutical and medical device companies worldwide, KOLs' have “proven to be 
among of the most effective and critical means of building product awareness in the 
medical and scientific communities.”31   Clinical leaders are well-respected experts of a 
specific disease or therapy with a strong reputation.  This reputation is typically 
strengthened by the number of publications they have and the rankings of the medical 
journals in which those articles are published in. Their roles vary, but often times clinical 
leaders are usually involved in bench testing the product before it goes to market.  It is 
thought that market leaders have a greater impact on general practitioners’ behaviour than 
clinical leaders, while clinical leaders have a greater impact on hospital-based physicians’ 





Evidence-Based Medicine (EBM) Strategy 
Evidence-based medicine (EBM) has become a “buzz word” in the medical arena.  For 
medical device companies, it has become increasingly important for survival in this 
competitive industry. Generally speaking, EBM uses thorough, well-designed research 
studies and empirical evidence to optimize decision-making (i.e., purchasing decisions).  
In the medical device industry, EBM primarily focuses on a product’s efficacy and 
effectiveness. Clinical efficacy is proven when there is evidence that the medical device is 
beneficial when used by experts in a research setting.33 Clinical effectiveness is proven if 
there is evidence that the medical device is beneficial when it is used by a representative 
sample of physicians in a normal clinical setting.34  This clinical marketing strategy is a 
tool used to optimize product introduction, adoption, life cycle management and business 
development of medical device innovations.35  The key objective of this strategy is to 
support customer adoption and market penetration of the medical device.  Unlike the 
pharmaceutical industry, in which product development is largely based on the 
development of strong clinical evidence, medical devices do not necessarily follow the 
same product development pathway.  
 
Additionally, newly launched medical devices are not always accompanied by clinical or 
economic evidence to support the product’s effectiveness.  Often times this will 
negatively impact the company’s commercial strategy because there is insufficient data 
linking the use of the product with a relevant clinical benefit in order to convince a 
clinician or a hospital manager of the advantages of this new medical device.36 It’s 
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preferable to launch a product that has the appropriate clinical data to support a well-
defined marketing strategy.  
Indicators of Success 
There are many different ways to measure the success of a marketing strategy.  Common 
indicators include sales/revenues, net income, devices deployed, rate of adoption and 
market penetration.  Each company must work with management to develop 
indicators/benchmarks of success and ways to reach those goals.  A major factor in the 
success or failure of a marketing strategy at any level is whether it fits in the market 
environment and if the offering meets the requirements of potential customers.  Today’s 
marketing goal is not only to increase market share, profitability or gain further customers 




When looking at high-tech products, such as medical device innovations, rate of adoption 
and market penetration are often used to define the company’s success.
39,40
  Rate of 
adoption is the speed at which innovation is adopted (the adoption curve).  Rate is usually 
measured by the length of time required for a certain percentage of the members of a 
social system to adopt an innovation.
41 
The rates of adoption for innovations are 
determined by an individual’s adopter category. In general, individuals who are 
considered early adopters require a shorter adoption period when compared to late 
adopters.  Market penetration is a measure of brand or category popularity. It is defined as 
the number of people who buy a specific brand or a category of goods at least once in a 
13 
 
given period, divided by the size of the relevant market population.
42 
Additionally, market 
penetration occurs when a company penetrates a market in which current or similar 




This research intends to assess the validity of two widely adopted clinical marketing 
strategies: Key Opinion Leader (KOL) strategies or Evidenced-based Medicine (EBM) 
strategies.  I hypothesize that embracing both a Key Opinion Leader (KOL) strategy and 
an Evidenced-Based Medicine (EDM) strategy will increase adoption of an innovative 
medical device in the USA.   
METHODS 
 
A qualitative study was designed in order to gain first-hand insight into these particular 
strategies. This study recruited participants who are employees of a medical device 
company that has developed an innovative Class II or Class III medical device.   
 
Participants were selected based on their role within the company.  The participants were 
involved in developing or executing the marketing strategies.  Once pre-screened, these 
individuals were interviewed one-on-one over the phone.  The participants were asked a 
series of 40 open-ended questions (See Appendix A).  Patton’s “Qualitative research and 
evaluation methods” was used a guide in developing the methods.
43
   The interviews 
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lasted approximately 45 – 60 minutes. The data were anonymized and analyzed.  In order 
to measure the success of the marketing strategies, participants were asked about levels of 
customer adoption and market penetration.  Adoption was measured based on number of 
devices deployed and sales. 
RESULTS 
 
A total of nine (9) individuals were interviewed.  Each interview was approximately 45 
minutes and resulted in roughly a ¾ page of bullet-pointed notes using shorthand writing 
or typed notes. The average word count per interview was 250. Each individual 
interviewed employed either an evidence-based medicine strategy or a key opinion-leader 
strategy (or both).  These strategies served as pillars of their marketing strategy.  
However, these strategies were not the only ones being executed.  The individuals 
interviewed were either the CEO or a person on the company’s marketing team.  All 
individuals interviewed were privately owned and employed less than 75 people. 
 
Table 1 (below) describes the interviewees. Particular categories were selected for the 
following reasons: 
- Sub industry: Medical devices are a broad category that includes 16 sub-
categories.  By further categorizing these companies, it will be easier to draw 
conclusions and relationships. 
15 
 
- Stage: The company’s stage of development (i.e., early, mid, late) is an important 
category as it is indicative of the time they have spent executing their business 
plan. 
- Person Interviewed: In conducting the interviews, there were people in various 
capacities within the company (i.e., CEO, marketing specialist, director of 
marketing, etc.).  This could potentially affect their responses as they would have 
a different perspective of the company’s state. 
- Sales: Once there are sales, it can be assumed that there is some degree of 
customer buy-in and therefore some degree of success. 
- Number (#) of KOLs: This category is part of my hypothesis to be assessed. 
- EBM Strategy: This category is part of my hypothesis to be assessed. 
 
Table 1: Summary of Respondents and their Respective Companies 
ANALYSIS/DISCUSSION 
The transcripts of the interviews were reviewed carefully and similarities in responses 
were noted and tallied.  The answers to specific questions were tallied and arranged in 
tables that can be found below.  Once the interviews were complete, a comparison 
ID Sub Industry Stage Person 
Interviewed 




1 Neurology Early CEO No 2 Yes 
2 Dental  Early CEO Yes 12 Yes 
3 Dental  Mid Marketing Yes 7 Yes 
4 Dental  Mid CEO Yes 12 Yes 
5 Orthopedics Mid CEO Yes 25 Yes 
6 Hematology Early CEO Yes 4 No 
7 Optometry Early CEO No 3 Yes 
8 Surgical Early Marketing No 5 Yes 
9 Hematology Late CEO Yes 8 No 
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allowed key findings (i.e., recurring themes) to be identified.  Following the identification 
of key findings, relevant quotes were extracted and mentioned in the discussion. In 
analyzing the qualitative information collected during the interviews, the following key 





Benefits of a KOL Strategy  
There are many benefits that stem from employing a KOL marketing strategy.  Aside 
from “increasing adoption”, the interviews revealed several other important benefits that 
arose from a KOL strategy; as listed in Table 2. 
Table 2: Benefits of a KOL Strategy 





ALL Convinces peers and colleagues to adopt 9 67% 
ALL  Disseminates scientific information in an “easy to 
swallow” format (i.e., medical education) 
9 67% 
ALL Tests the product during development  9 67% 
ALL Provides exposure/publicity 9 67% 
ALL Builds credibility and validates product 9 67% 
1, 2, 4, 
5, 6, 9 
Identifies new opportunities and indications for use 11 83% 
1, 2, 3, 
8, 9 
Provides feedback to help guide product 
development 
7 60% 
1, 2, 3, 
5, 8 





From these results, it is evident that all respondents agreed on the importance of a KOL 
strategy.  As Respondent 5 remarked: “KOLs are the best marketing strategy a medical 
device company can have.  An evidence-only strategy would simply not work”.  
Respondent 6 concurred: “KOLs are the most powerful tool of all”.  It should also be 
noted that of the six companies that used KOLs to identify new opportunities and 
indications for use 83% had sales. Perhaps this strategy should be prioritized. 
 
Drawbacks of a KOL Strategy 
KOL strategies are extremely beneficial; however, there are certainly drawbacks to this 
approach that were discussed during the interviews. In order to gain credibility and 
scientific validation, companies often partner with academia.  This results in KOLs 
becoming early users but not early customers. While the KOLs were always interested in 
running clinical studies and publishing results, their visibility often makes them 
conservative.  Academics often delay real adoption (i.e., purchasing the product) until the 
new technologies are well proven. Publications, clinical trial leadership, and scientific 
advisory board membership therefore do not always indicate an early adopter.  When 
1, 5, 7 Guides regulatory compliance 10 33% 
1, 5, 8 Helps guide product purchases 11 33% 
1, 2 Helps with competitive analysis and comparison 7 50% 
7 Guides company’s bioethics 3 No 
1 Supports patient advocacy 2 No 
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early adopters tell you that your solution resolves an important problem, you’ll know 
you’re on the right track. 
 
In several companies, KOLs were paid by the company for their services. This often 
creates a professional bias and the KOL can become less influential, damaging the overall 
marketing strategy.  In discussing this strategy with one company, they would pay their 
KOLs $5,000 for a single event, in addition to all of their travel expenses.  Oppositely, 
another company recruited KOLs who were genuinely interested in their product for 
research purposes.  In this scenario, the KOL bought the product at full price and 
championed it for free. Unfortunately, conflicts of interest will arise when clinicians 
become marketing and PR “mouthpieces” for new medical devices. 
 
Interestingly, as summarized in Table 3 (below), this comparison of paid versus unpaid 
KOLs suggests that sales were achieved 100% of the time if the KOL is paid.  In the 
companies that did not pay the KOLs, sales were only achieved 50% of time. I conclude 
that paying KOLs may increase the likelihood of achieving sales. 
 









Avg. # of 
KOLs 
Sales EBM 
2, 3, 5 Yes 15 100% 100% 
1, 4, 6 – 9  No 6 50% 67% 
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Identifying and recruiting KOLs  
Table 4 (below) lists the methods used by the respondents to identify and recruit KOLs.  
Asking for references from clinical collaborators and networking at conferences and 
exhibitions were two methods used by all of the respondents.  In looking at the percentage 
of companies with sales, these methods seem to be the most successful.  The six methods 




Table 4: KOL Recruitment 
ID Recruiting Method Avg. # of KOLs Sales 
ALL Asking clinical collaborators for 
recommendations 
9 67% 
ALL Networking at conferences and exhibitions 9 67% 
1, 2, 4, 
5, 7 
Networking with industry colleagues 
(device industry execs, VC’s, consultants) 
who have previously sold to this customer 
segment 
11 60% 
1, 2, 4, 
5, 7, 8 
Reading the literature that has been 
produced and looking at the literature being 
produced in segment.  Tracking down the 
researchers and clinicians that are doing 
work in your area and recruit them. 
10 50% 
2, 3, 8 Identifying competitive or non-competitive 
products in the same segment, and seeking 
out the early buyers and their KOLs 
8 66% 
1, 5 Approaching candidates on scientific 
advisory boards of previous or other 
existing startups in segment 
13 50% 
 
Types of KOLs  
20 
 
The interviews revealed that there are different types of KOLs.  In a strong KOL 
portfolio, there will be many different types of KOLs that will satisfy the many different 
roles.  KOLs differ on several indices, which I will outline: 
 
 Degree of influence: Some KOLs are more influential and powerful than others. Well 
respected, and most recognized KOLs tended to be older and very well versed in the 
particular segment.  As Respondent 2 said, “Mr. XXXX is the Dental God.  He has 
been around forever, and everyone listens to him”.  Respondents 1, 2, and 5 allowed 
me to conclude that each KOL has a different reputation in the industry based on their 
contribution and their general level of activity.  Getting the “top dog” in the industry 
is the goal. This individual is typically 60+ years old. 
 Type of influence: KOLs varied in who they had influence on, whether it be 
peers/colleagues, consumers/patients, and hospital administrators. 
 Role in the company: Depending on their agreement, KOLs served various roles.  
Some KOLs were extremely active in clinical research and product development, 
while others were merely spokespeople for the company and product. As Respondent 
2 said, “We have some guys good at public speaking, while others are better one-on-
one.”  In order to manage this, the company developed a KOL spreadsheet that 
outlines/details each KOL and their specific roles, their strengths and their 
weaknesses. 
 
KOLs are often first customers, but not always 
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In almost all discussions, the KOLs recruited by the company became the company’s first  
buyer.  As shown in Table 5, the situation varied, with the customer being either focused 
on research/academia or a practicing clinician with little ties to research.  In some cases, 
however, the KOL was given the product at no cost.  This occurred when the KOL was a 
researcher.  Given tight budgetary restraints in academia, and the fact that researchers can 
help companies with their clinical research, it is no surprise that these KOLs were given 
product at no cost. 
Table 5: KOL Buying Behaviour  
 
FDA vs. EBM 
The Food and Drug Administration (FDA) is a federal agency in the United States that 
acts as the governing body for many different things, including medical devices.  In the 
medical device industry, regulatory approval is necessary in order for the product to be 
legally sold.  All companies interviewed had dealt with the FDA in some capacity, as the 
medical devices being developed required some level of approval.  It was the general 
consensus that the FDA merely ensures the product is safe and the risks associated with 
use are mitigated – that is it.  The bar is very low in terms of clinical validation, clinical 
efficacy and clinical effectiveness.  EBM goes above and beyond evidence required by 
regulatory bodies. However, in speaking with numerous individuals from a variety of 
industries, it was noted in one conversation that EBM was not necessary as the 
ID Purchased VS. Given Researcher or Practicing Clinician Sales 
2, 3, 4, 
5, 6 
KOL purchased product Practicing clinician 100% 
2, 3 KOL was given product Researcher 100% 
22 
 
requirements put forth by the FDA were sufficient enough to produce sales.  This 
conversation also revealed that the FDA had recently increased the evidence required for 
approval.  With that said, each company’s EBM strategy was unique in strength and 
depth.  It should be noted that the degree of evidence required depends on specialty and 
product. 
Table 6: FDA vs. EBM 
 
Interestingly, as outlined in Table 6, only two companies did not employ an EBM strategy 
(ID 6 and 9); however respondents 1, 2, and 3 claimed that FDA approval was sufficient 
for customer buy-in yet they still employed an EBM strategy.  Respondents 6 and 9 both 
achieved sales, while Respondent 1 did not, despite employing an EBM strategy.  This 
result poses two questions: 1) When is an EBM strategy necessary? and 2) Under what 
conditions is it sufficient to obtain only FDA approval?   
 
EBM is very cumbersome and expensive  
Despite the hype and importance that surrounds EBM, it is a very expensive and time-
consuming endeavor.  Clinical studies can run anywhere from thousands, to millions, 
with an average cost in the tens of thousands.
44
  An EBM strategy must be carefully 
planned and executed by trained and experience professionals.  KOLs play a very 
important role in guiding this strategy, as they are the clinicians on the ground level. 
Table 7 (below) suggests that just one clinical study can cost tens of thousands, even 
ID FDA vs. EBM Sales 
1, 2, 3, 6, 9 FDA approval is sufficient evidence for customer buy-in 60% 
5, 7, 8 EBM is required for customer buy-in 33% 
23 
 
hundreds of thousands. No data was collected from Respondents 3 and 4 regarding this 
topic. 
Table 7: FDA vs. EBM 
 
 
EBM and KOL strategies can leverage other strategies 
With a KOL and EBM strategy being implemented, the companies interviewed also 
enjoyed the benefits of leveraging another strategy, namely a reimbursement strategy.  
This strategy was not listed in the literature review that I completed during my research.  
As these medical devices are considered innovations, sometimes there is a not an 
appropriate billing code associated with the device or the procedure involved. Although 
there are usually predicate devices, and pre-existing billing codes that can be used, having 
a specific billing code is much more desirable. If there is no billing code, the doctor 
cannot charge the patient and therefore the device will not be sold.  Subsequently, a solid 
reimbursement strategy is necessary to ensure that the user can get a sufficient ROI.  
Respondent 5 indicated that their KOLs were able to help create novel billing codes for 
their device.  Their ability to do so was fuelled by clinical evidence that was produced 
from the EBM strategy.  This is significant as the link between reimbursement strategy 
and marketing strategy did not appear during my review of the literature review. 
 
ID Cost of One Clinical Study 
1, 2 Upwards of $75,000 - $100,000 
5, 7, 8 $100,000+ 
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KOL and EBM: The Chicken or The Egg 
An interesting relationship exists between a KOL marketing strategy and an EBM 
strategy in that historically EBM was in-part developed to supplement a KOL strategy.  
EBM goes above and beyond most required evidence set forth by the FDA.  An EBM 
strategy advocates that purchasing decisions, of medical devices for example, should be 
based on scientific evidence as opposed to the perceptions of doctors and potentially 
biased views of KOLs. In order to recruit and retain KOLs, it is important for the 
company to have strong clinical evidence.  However, KOLs play a defining role in 
developing the EBM strategy.  There is clearly a level of evidence beyond FDA approval 
that is required of medical device companies in order to attract suitable KOLs.  Table 8 
(below) summarizes the responses regarding this question. As Respondent 5 said, “As 
long as there is some scientific proof, not even necessarily FDA approval,  KOLs are able 
to see the bigger picture, the science, and they will be your champions”. 
Table 8: What Comes First: KOL strategy or EBM strategy? 
ID Comments 
1, 2 KOLs come first, using minimal evidence to support the idea 
5, 7 Extensive evidence must be established before attracting KOLs 
 
 
Niche VS. Mainstream Products 
Products can be classified based on their market size and potential for ubiquity.  A niche 
product is made and marketed for use in a small and specialized but profitable market, 
while a mainstream product has a larger market size and is adopted more broadly.  There 
were distinct differences in responses between companies that sold niche products versus 
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companies that developed mainstream products.  Of the companies that developed niche 
products, the following similarities were revealed: 
Table 9: Characteristics of Companies with Niche Products 
ID Comments 
5, 6, 8, 9 KOLs were not paid.  This could be because the researcher was genuinely 
interested in the product and was intrigued by its applications 
 
5, 6, 8, 9 “Sales” wasn’t the only main indicator of success.  For example, one 
respondent indicated the “customer service” was a primary indicator of 
success. 
 
5, 6, 8, 9 FDA approval was difficult, but it was generally enough evidence for 
customer buy-in. 
5, 6, 8, 9 Advertising budget is virtually non-existent. 
 
In comparing companies with niche products vs. mainstream products in Table 10 
(below), companies with niche products were more likely to: 
- Have sales (i.e., be successful) 
- Have a higher number of KOLs 
- Not pay KOLs 
- Not employ an EBM strategy 
 
Table 10: Comparison of Companies with Niche Products vs. Mainstream Products 







5, 6, 8, 9 Yes 75% 11 50% 50% 
1 – 4, 7 No 60% 7 40% 100% 
 
 
“Sales” as a Key Indicator of Success 
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During each interview, the question of “how do you measure success?” was posed.  In 
every interview, the first response was always sales.  The individuals being interviewed 
remained tight-lipped regarding specifics, but stated their success was tied tightly to their 
overall business strategy. Another recurring theme included whether or not the company 
was cash-flow positive.  Although all companies in question were not cash-flow positive, 
a measure of success and a primary goal was to firstly establish themselves as a company 
with sales, followed by becoming cash flow positive.  Another interesting response to this 
question by Respondent 9 was “customer service”.  This respondent indicated having a 
quality product and a happy customer was an indicator of success. In fact, this respondent 
delivered annual surveys to all their customers in order to gauge their level of overall 
satisfaction.  Initially, this was not expected.  Originally, market penetration and speed of 
adoption were thought to be the primary indicators of success.  Following the interviews, 
the data revealed otherwise. 
 
Of the nine companies interviewed, three of the companies did not have sales.  That is, 
they had developed a product but had not achieved sales by selling to customers.  This 
could be due to a number of factors that will be discussed.  If sales is an indicator of 
success, what separates the three companies with no sales, from the 6 companies with 
sales.  I summarized the responses from these two groups in Table 11. 
Table 11: Comparison of Companies with Sales vs. Without Sales 
Respondents Sales Avg.  
# of KOLs 






1, 7, 8 No 3 0% 100% 33% 100% 




Based on this comparison, the lack of sales can possibly be attributed to the number of 
KOLs or the current stage of the company.  The latter would seem to make more sense, as 
early stage companies are in their infancy and require more time to establish themselves 
in the market.  Particularly in the medical device industry, as gaining regulatory approval 
can take years.  It should also be noted that companies that pay their KOLs are more 
likely to achieve sales.  Of the companies that do not have sales, they also do not pay their 
KOLs.  It is interesting to note that of the companies with sales, only 67% of them 
employ an EBM strategy. 
CONCLUSION 
This study assessed whether embracing both a Key Opinion Leader (KOL) strategy and 
an Evidenced-Based Medicine (EDM) strategy will increase adoption of an innovative 
medical device in the USA.  Based on the literature review and the results of this study, 
key opinion leaders and evidence-based medicine are critical components of medical 
device marketing strategies. The KOL strategy stood out as highly important in both the 
literature and the study, while the EBM strategy was not always necessary.  It is clear that 
engaging KOLs is necessary to build credibility and influence peers.  The interviews 
revealed that there were many different benefits associated with adopting a KOL strategy, 
not just increased product adoption.  The most common benefits included bench-testing, 
exposure, publicity, building credibility and disseminating scientific information.  
However, these benefits come at a cost, as it was revealed that paying KOLs may have a 
positive impact on success.  Conveniently, there are also various ways in which KOLs 
can be identified, with networking and requesting references being the most common.  
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Consistent with real-life experience, the results suggested that academic KOLs are 
unlikely to purchase the technology, while practicing clinicians will be the first 
customers.   
 
With regards to EBM strategies, clinical evidence to support both economic viability and 
patient welfare is essential to medical device innovation.  Most of the people interviewed 
argued that a KOL strategy is more important and more powerful than an EBM strategy.  
However, in order to attract and retain KOLs, it is important to have strong, empirical 
evidence to support claims.  Conveniently, these clinical claims may be achieved through 
FDA certification. When compared to the FDA, an EBM strategy is much more robust 
and requires proof of not only safety, but also economical effectiveness and efficacy.  The 
FDA merely ensures safety, while an EBM approach takes into account cost effectiveness 
and clinical outcomes (i.e., better, faster, stronger cheaper).  As noted in the results, an 
EBM strategy can be very costly and therefore some companies may not be able to afford 
or justify spending thousands of dollars on clinical studies.  Depending on the product, 
FDA approval may be all the support and evidence a company needs to gain achieve 
sales. 
 
The hypothesis that a strong KOL strategy and a strong EBM strategy is critical for 
success finds qualified support.  Interestingly, one respondent was able to leverage a 
reimbursement using a KOL and EBM strategy.  Additionally, the results suggested that 
companies with niche products may have an advantage in terms of sales and the need to 
employ an EBM strategy.  Measurements of success varied between companies; however, 
measuring sales was a commonality between all companies interviewed.  While each 
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strategy on their own has holes, a combination of both a KOL strategy and an EBM 
strategy may increase the likelihood of sales in the medical device industry.  The data 
presented in this paper uses a small sample size (n = 9) and therefore I recommend that in 
order to make concrete claims, further research must be carried out.   Further research 
regarding marketing in the life sciences industry as a whole is necessary because of the 
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APPENDIX A 
 
MRP – Victoria Smith 
List of Questions 
 
Qualifying 
- What is your position in the company? 
- Who is responsible for the development and execution of the marketing plan? 
- When was/will be product launch? 
- Describe your product  
- Who is your customer? 
 
General 
- Tell me about the marketing strategies your company uses to increase product adoption 
- How successful do you think these strategies have been? 
- Describe your company’s indicators of success? 
 
Key Opinion Leader (KOL) Questions 
- What is your opinion regarding KOL strategies? 
- What has been your experience with engaging KOLs in the medical device industry? 
- What has your company done to engage KOLs? 
- What benefits have resulted from engaging KOLs? 
- At what point in the product life cycle have you engaged KOLs? 
- What do you think is the best method for identifying KOLs? 
- What are some of the indicators of a suitable KOL? 
- How many KOLs have you targeted?  
- How many are on board? 
 
Evidenced-Based Medicine (EBM) Questions 
- How do you define the “clinical questions” your product studies must answer? 
- How does the relationship between the scientific team and the marketing team affect 
clinical studies? 
- The FDA requires a certain level of evidence. How do you feel this level compares to 
the level your potential customer requires? 
- Following FDA approval, how many more (if any) clinical studies were conducted or 
plan to be conducted? 
- Describe the amount of evidence (in terms of clinical studies, case studies, etc.) that has 
been collected  
- What type of empirical evidence do you collect (randomized, triple-blind, placebo, etc)? 
- Which type of evidence do you feel is most compelling and why? 





                                                                                                                                                                     
Measurable Results 
- How do you measure the effectiveness of your company’s marketing strategies? 
- How do you measure speed of adoption?  
- How do you measure market penetration? 
- What other measures do you use? 
- What are your yearly sales? (Get multiple figures). 
- How many devices do you have deployed? In how many facilities? 
- What is your total addressable market? 
 
Ending 
- That covers the items I wanted to discuss with you.  Is there anything else you would 
like to add? 
- Is there anything you think I should have asked you, but didn’t? 
 
 
 
 
 
 
 
